Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Product Details
Z2345MP
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG2b, kappa
Class
Monoclonal
Type
Antibody
Clone
ZM23
Immunogen
Recombinant human GCDFP-15 protein fragment (aa 41-146)
Conjugate
Form
Liquid
Purification
Protein A
Storage buffer
tris with BSA, NP-40
Contains
<0.1% sodium azide
Storage conditions
4° C
Shipping conditions
Wet ice
Product Specific Information
This product is diluted and in a ready-to-use formulation.
A recommended positive control tissue for this product is Breast Carcinoma, however positive controls are not limited to this tissue type.
The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.
It recognizes a protein of 15 kDa, identified as Gross cystic disease fluid protein 15 (GCDFP-15). It is a major protein component of benign breast gross cysts. It is a known marker of breast cancer, as it is found in approximately 50% of all breast cancer specimens. GCDFP-15, also known as PIP, for prolactin inducible protein, is a prolactin and androgen-controlled protein. This antibody is useful in the identification of metastatic breast carcinoma, or fluid analysis.
Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.
A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.
Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.
Target Information
Gross cystic disease of the breast is benign premenopausal disorder in which cysts are a predominant pathological lesion. These cysts appear to be formed from excessive apocrine cystic secretions. This fluid is composed of several glycoproteins including a unique 15kDa monomer protein, Gross Cystic Disease Fluid Protein-15 (GCDFP15). Cytosolic analysis of normal tissue specimens from all major organs has demonstrated GCDFP15 in apocrine epithelia, lacrimal, ceruminous and Moll's glands and in numerous serous cells of the submandibular, tracheal, bronchial, sublingual and minor salivary glands. GCDFP15 and prostate specific antigen are co-expressed in androgen receptor-positive breast tumours.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: gcdfp 15; GCDFP-15; gp17; Gross cystic disease fluid protein 15; HGNC:8993; Prolactin-induced protein; Prolactin-inducible protein; SABP; Secretory actin-binding protein
Gene Aliases: GCDFP-15; GCDFP15; GPIP4; PIP
UniProt ID: (Human) P12273
Entrez Gene ID: (Human) 5304
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support